Urologisk forskningsgruppe

Erik Skaah​eim Haug (forskningsgruppeleder)

Stillingstittel og foretak: Overlege, urologisk seksjon, Sykehuset i Vestfold
Akademisk tittel: MD PhD
E-post: erik.haug@siv.no 
Telefon: 33 34 33 07​

Sven ​Löffeler

Stillingstittel og foretak: Overlege, urologisk seksjon, Sykehuset i Vestfold
Akademisk tittel: MD PhD
E-post: sven.loffeler@siv.no 
Telefon: 33 34 23 73

​Elisabeth Aune

Stillingstittel og foretak: Overlege, urologisk seksjon, Sykehuset i Vestfold
Akademisk tittel: MD
E-post: elisabeth.aune@siv.no 
Telefon: 33 34 34 51

​​Stein Øverby

Stillingstittel og foretak: Avdelingsoverlege, urologisk seksjon, Sykehuset i Vestfold
Akademisk tittel: MD
E-post: stein.overby@siv.no 
Telefon: 33 34 32 75

​​Karolina Cyll

Stillingstittel og foretak: Forsker, urologisk seksjon, Sykehuset i Vestfold
Akademisk tittel: PhD
E-post: Karolina.Cyll@siv.no 
Telefon: 403 83 705

Rasmus Nilsson

Stillingstittel og foretak: Overlege, urologisk avdeling, Sykehuset i Telemark
Akademisk tittel: MD, PhD-stipendiat 
E-post: Rasmus.Nilsson@sthf.no​ 

Birgitte Carlsen

Stillingstittel og foretak: Patolog, Patologisk avdeling, Sykehuset i Vestfold
Akademisk tittel: MD, PhD-stipendiat
E-post: birgitte.carlsen@siv.no ​

Thomas Fredrik Næss-Andresen 

Stillingstittel og foretak: Overlege, urologisk avdeling, Vestre Viken HF
Akademisk tittel: MD
E-post: ThomasFredrik.Naess-Andrsen@vestreviken.no 

Karin Skogstad

Stillingstittel og foretak: Studiesykepleier, registeransvarlig, Urologisk avdeling, Sykehuset i Vestfold
Akademisk tittel: MSc 
E-post: karin.skogstad@siv.no 
Telefon: 33 34 10 75​

May Lisbeth Plathan

Stillingstittel og foretak: Studiesykepleier, kirurgisk poliklinikk, Sykehuset i Vestfold
Akademisk tittel: MSc
E-post: May.Lisbeth.Plathan@siv.no 
Telefon: 33 34 10 75​

Kirsti Sanboe​ Langsrud

Stillingstittel og foretak: Studiesykepleier, kirurgisk poliklinikk, Sykehuset i Vestfold
E-post: Kirsti.Sandboe.Langsrud@siv.no 
Telefon: 33 34 10 75

​​Hege M. Bakke

​Stillingstittel og foretak: Helsesekretær, kirurgisk kontor, Sykehuset i Vestfold
E-post: hege.bakke@siv.no 
Telefon: 33 34 28 29

Carl Fredrik Knobloch​

Pernille Simo​nsen

​Hilde Skarsbø Sørensen

Forskningssekretær, Sykehuset i Vestfold 

 

SPCG 19-studien: «En randomisert, multisenterstudie for å måle effekten på totaloverlevelse og livskvalitet av umiddelbar kurativ behandling sammenlignet med standard konservativ behandling av eldre menn (≥ 75 år) med ikke-metastatatisk, høy-risiko prostatakreft»
Prosjektleder er Sven Löffeler, Sykehuset i Vestfold

ESTO 2-studien: «Effekt av atorvastatin på prostatakreftprogresjon etter oppstart av terapeutisk kastrasjonsbehandling – lipid metabolisme som en ny prediktor av prostatakreftprogresjon – ESTO 2»
Prosjektleder Sven Löffeler, Sykehuset i Vestfold

Prognostiske faktorer I prostatakreft​
Prosjektleder: Erik Skaaheim Haug, Sykehuset i Vestfold

Diagnostics and detection of prostate cancer with MRI
Prosjektleder: Erik Skaaheim Haug

Aktiv overvåkning Pluss (AS ): Lokal tumor kontroll med hjelp av HIGH-INTENSITY FOCUSED ULTRASOUND (HIFU) hos pasienter med avkapslet (tidlig) prostatakreft
Prosjektleder: Sven Löffeler, Sykehuset i Vestfold​

Kartlegging av mikrobiologi og risiko for infeksjon etter radikal cystectomi - CystInf-studien
Prosjektleder: Erik Skaaheim Haug, Sykehuset i Vestfold

Health related quality of life, adverse effects, and work life in relation to clinical, socio-demographic, and psychological factors in men with localized prostate cancer
Pro​sjektleder: Erik Skaaheim Haug, Sykehuset i Vestfold

Forekomst og prognostisk betydning av tumorinfiltrasjon i lymfekar og blodkar ved blærekreft behandlet med radikal cystectomi
Prosjektleder: Erik Skaaheim Haug, Sykehuset i Vestfold

Forekomst og prognostisk betydning av tumorinfiltrasjon i lymfekar og blodkar ved blærekreft behandlet med radikal cystectomiProsjektleder: Erik Skaaheim Haug, Sykehuset i Vestfold

Kartlegging av pasienter med langkommet Prostatakreft (CRPC) i Vestfold 2009-2014
Prosjektleder: Sven Löffele​r

En urinbasert biomarkørtest for blærekreft
Prosjektleder: Guro Elisabeth Lind​​

SPCG-17-Studien
​Prosjektleder: Anna Bill-Axelson, Uppsala Universitet​

​

2024:

• Kimie Oedorf, Erik Skaaheim Haug, Fredrik Liedberg, Riikka Järvinen, Sigidur
  Gudjonsson, Tomas Jerlström, Gigja Gudbrandsdottir, Jørgen Bjerggaard Jensen and Gitte Wrist Lam. Perioperative management of upper urinary tract carcinoma in the Nordic countries. BMC Urology 2024; 24. https://doi.org/10.1186/s12894-024-01515-7 
• Elin Gustavsen, Erik Skaaheim Haug, Ellinor Haukland, Ragnhild Heimdal, Eva Stensland, Tor Åge Myklebust, Beate Hauglann. Geographic and socioeconomic variation in treatment of elderly prostate cancer patients in Norway - a national register-based study. Research in Health Services & Regions 2024; 3:8. https://doi.org/10.1007/s43999-024-00044-y
• Karolina Cyll, Erik Skaaheim Haug, Manohar Pradhan, Ljiljana Vlatkovic, Birgitte Carlsen, Sven Löffeler, Wanja Kildal, Karin Skogstad, Frida Hauge Torkelsen, Rolf Anders Syvertsen, Hanne A. Askautrud, Knut Liestøl, Andreas Kleppe, and Håvard Danielsen. DNA ploidy and PTEN as biomarkers for predicting aggressive disease in prostate cancer patients under active surveillance. Br J Cancer 2024. 
• Sven Löffeler, Helena Bertilsson, Christoph Müller, Kirsti Aas, Hege Sagstuen Haugnes, Bjørg Aksnessæther, Maiju Pesonen, Kristian Thon, Torgrim Tandstad, Teemu Murtola, Mads Hvid Poulsen, Tobias Nordstrøm, Maria Nyre Vigmostad, Fredrik Ottosson, Karin Holmsten, Ola Christiansen, Marit Slaaen, Erik Skaaheim Haug, Anne Holck Storås, Lars Asphaug, Antti Rannikko, Klaus Brasso. Protocol of a randomised, controlled trial comparing immediate curative therapy with conservative treatment in men aged ≥75 years with non‐metastatic high‐risk prostate cancer (SPCG 19/GRand‐P. BJU Int 2024. https://DOI.org/10.1111/bju.16314 
• Fredrik Jäderling, Martin Bergman, Jan Chandra, Ashkan Mortezavi, Wolfgang Picker, Erik Skaaheim Haug, Martin Eklund, Tobias Nordström. Tailoring biopsy strategy in the MRI-fusion prostate biopsy era: systematic, targeted or neither? BMC Urology 2024; 24: 168. https://doi.org/10.1186/s12894-024-01553-1 
• Nilsson R, Næss-Andresen TF, Myklebust TÅ, Bernklev T, Kersten H, Haug ES. The association between pre-diagnostic levels of psychological distress and adverse effects after radical prostatectomy. BJUI Compass 2024; 1-10. http://doi.org/10.1002/bco2.334 

2023:

• Mona Otrebski Nilsson, Kirsti Aas, Tor Åge Myklebust, Ylva Marie Gjelsvik, Erik Skaaheim Haug, Sophie Dorothea Fosså, Tom Børge Johannesen. Do all prostate cancer patients want, and experience Shared Decision Making prior to curative treatmen. Scand J Urol 2023, 58: 133-140. 
• MacLennan S, Azevedo N, Duncan E, Dunsmore J, Fullwood L, Lumen N, Plass K, Ribal MJ, Roobol MJ, Nieboer D, Schouten N, Skolarus TA, Smith EJ, N'Dow J, Mottet N, Briganti A; Pan-European National Urological Society IMAGINE Collaborative. Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries. Eur Urol. 2023 May;83(5):393-401. 
• Erik Skaaheim Haug, Tor Åge Myklebust, Patrick Juliebø-Jones, Lars Anders Rokne Reisæter, Kirsti Aas, Arne Stenrud Berg, Christoph Müller, Bjørn Hofmann, Øystein Størkersen, Kim L. Nilsen, Tom Børge Johannesen, Christian Beisland. Impact of prebiopsy MRI on prostate cancer staging: Results from the Norwegian Prostate Cancer Registry. BJUI Compass 2023; 1-8. https://doi.org/10.1002/bco2.214 
• Hofmann B, Haug ES, Kjelle E, Andersen ER. Increased magnetic resonance imaging in prostate cancer management – what are the outcomes? J Eval Clin Pract 2022. https://doi.org/10.1111/jep.13791 

2022

• ​​​Peters M, Eldred-Evans D, Kurver P, Falagario UG, Connor MJ, Shah TT, Verhoeff JJC, Taimen P, Aronen HJ, Knaapila J, Montoya Perez I, Ettala O, Stabile A, Gandaglia G, Fossati N, Martini A, Cucchiara V, Briganti A, Lantz A, Picker W, Haug ES, Nordström T, Tanaka MB, Reddy D, Bass E, van Rossum PSN, Wong K, Tam H, Winkler M, Gordon S, Qazi H, Boström PJ, Jambor I, Ahmed HU. Predicting the Need for Biopsy to Detect Clinically Significant Prostate Cancer in Patients with a Magnetic Resonance Imaging-detected Prostate Imaging Reporting and Data System/Likert ≥3 Lesion: Development and Multinational External Validation of the Imperial Rapid Access to Prostate Imaging and Diagnosis Risk Score. Eur Urol. 2022 Aug 10:S0302-2838(22)02537-4. 
• *T Sneha Parekh, Parita Ratnani, ,,.. Erik Haug,.., Ash Tewari. Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging Outcome Database, and European Randomized Study of Screening for Prostate Cancer Risk Calculator. Eur Urol Open Sci 2022; 45-4554. https://doi.org/10.1016/j.euros.2022.04.017
• Siltari A, Riikonen J, Koskimäki J, Pakarainen T, Ettala O, Boström P, Seikkula H, Kotsar A, Tammela T, Helminen M, Raittinen PV, Lehtimäki T, Fode M, Østergren P, Borre M, Rannikko A, Marttila T, Salonen A, Ronkainen H, Löffeler S, Murtola TJ. Randomised double-blind phase 3 clinical study testing impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy: study protocol. BMJ Open. 2022 Apr 29;12(4):e050264. https://doi.org/10.1136/bmjopen-2021-050264
• Nilssen Y, Brustugun OT, Eriksen MT, Guren MG, Haug ES, Naume B, Schlichting E, Møller B. Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015-2016. BMC Cancer 2022; 220: https://doi.org/10.1186/s12885-022-09306-9 
• Haug ES. Content is king: The electronic format is just a first step in the digital evolution of medical information. Scand J Urol 2022; 56(2): https://doi.org/10.1080/21681805.2022.2052956
• Christiansen O, Bratt O, Kirkevold Ø, Benth JS, Manoharan P, Selnes A, Haug ES, Slaaen M. Predictors of upgrading from low-grade cancer at prostatectomy in men with biparametric magnetic resonance imaging. Cent European J Urol 2022; 75:35-40. https://doi.org/10.5173/ceju.2021.0217
• Karolina Cyll, Sven Löffeler, Birgitte Carlsen, Karin Skogstad, May Lisbeth Plathan, Martin Landquist, Erik Skaaheim Haug. No significant difference in intermediate key outcomes in men with low- and intermediate risk prostate cancer managed by active surveillance. Sci Rep. 2022 Apr 25;12(1):6743.  

202​​1​

• Carlsen B, Klingen TA, Andreassen BK, Haug ES. Tumor cell invasion in blood
  vessels assessed by immunohistochemistry is related to decreased survival in patients with bladder cancer treated with radical cystectomy. Diagnostic Pathology 2021; 16; 109 https://doi.org/10.1186/s13000-021-01171-7
• Karolina Cyll, Andreas Kleppe, Joakim Kalsnes, Ljiljana Vlatkovic, Manohar Pradhan, Wanja Kildal, Elin Ersvær, Kari Anne Tobin, Trine M. Reine, Håkon Wæhre, Bjørn Brennhovd, Hanne A. Askautrud, Tarjei S. Hveem, Erik Haug, Håvard Danielsen. PTEN and DNA ploidy status by machine learning in prostate cancer. Cancers 2021, 13(17), 4291
• Nilsson R, Næss-Andresen TF, Myklebust TÅ, Bernklev T, Kersten H, Haug ES. Fear of recurrence in prostate cancer patients: a cross-sectional study after radidical prostatectomy or active surveillance. Eur Urol Open Sci. 2021; 3; 44-51.
• Körner SK, Dreyer T, Olsson H, Haug ES, Jerlström T, Boström PJ, Gudjonsson S, Jensen JB. Which Data are Available in Central Registries on Bladder Cancer Patients in the Five Nordic Countries. Scand J Urol 2020; 55(2): 135-141
• Almås B, Øverby S, Halvorsen OJ, Reisæter LAR, Carlsen B, Beisland C. Preoperative predictors of pathological tumour stage and prognosis may be used when selecting candidates for intensified treatment in upper tract urothelial carcinoma. Scand J Urol. 2021 Apr;55(2):100-107.

202​​0​​

• Blindheim A, Fosså S, Babigumira R, Myklebust TÅ, Haug ES, Arum CJ, Andreassen B. T1 Bladder cancer I Norway: treatment and survival. Scand J Urol 2020.
• Hari T. Vigneswaran, Thorgerdur Palsdottir, Henrik Olsson, Erik S. Haug, Wolfgang Picker, Sven Löffeler, Henrik Grönberg, Martin Eklund, Tobias Nordström. Biomarker Discrimination and Calibration with MRI-targeted Biopsies: An analysis with the Stockholm3 test. Prostate  Cancer Prostatic Dis 2020 24(2): 457-464
• Nilssen Y, Brustugun OT, Eriksen MT, Haug ES, Naume B, Møller B. Patient and tumour characteristics associated with inclusion in Cancer Patient Pathways in Norway in 2015–2016. BMC Ca 2020; 20 (1): 488
• Anna Lantz, Erik Skaaheim Haug, Wolfgang Picker, Fredrik Jäderling, Ashkan  Mortezawi, Tobias Nordström. Effect of information on prostate biopsy history on biopsy outcomes in the era of MRI-targeted biopsies. World J Urol 2020
• Mortezavi A, Palsdottir T, Eklund M, Chellappa V, Saba K, Ankerst DP, Haug ES, Murugan SK, Grøneberg H, Nordström T. Head-to-head comparison of traditional image- and biomarker-based prostate cancer risk calculators. Eur J Urol Focus 2020; 22
• Normann C, Opheim R, Andreassen B, Bernklev T, Haug ES. Health-related quality of life after radical cystectomy among Norwegian men and women compared to the general population. Scand J Urol
• Nilsson R, Dahl A, Bernklev T, Kersten H, Haug ES. Work status and work ability after radical prostatectomy or active surveillance for prostate cancer. Scand J Urol 2020; 1-7
• Löffeler S, Fawad H, Halland A, Beisland C, Haug ES. Non-metastatic prostate cancer: Rationale for conservative treatment and impact on disease-related morbidity and mortality in the elderly. Scand J Urol
• Ugo Giovanni, Falagario, Ivan Jambor, Anna Lantz, Otto Ettala, Armando Stabile, Pekka Taimen, Hannu J. Aronen, Juha Knaapila, Giorgio Gandaglia, Nicola Fossati, Alberto Martini, Vito Cucchiara, Wolfgang Picker, Erik Haug, Ileana Montoya Perez, Parita Ratnani, Kenneth Haines, Sara Lewis, Nair Sujit, Oscar Selvaggio, Francesca Sanguedolce, Luca Macarini, Luigi Cormio, Tobias Nordström, Ash Tewari, Alberto Briganti, Peter J. Boström, Giuseppe Carrieri. Combined use of PSA density and Magnetic Resonance Imaging for prostate biopsy decision planning:  Retrospective multi-institutional study using the PRostate Mri Outcome Database (PROMOD). Eur Urol Onc 2020 (20) 30142-5
• Fosså SD, Aas K, Müller C, Berm MJ, Tandstad T, Lilleby W, Kvåle R, Gulbrandsen J, Haug ES, Myklebust TÅ. Definitive radiotherapy in Norway 2006-2015: Temporal trends, performance and survival. Radiotherapy and Oncology 2020
• Almås B, Øverby S, Halvorsen OJ, Reisæter LAR, Assmus J, Carlsen B, Loe A, Beisland C. Tumour architecture, grade and location remain predictors of non-organ-confined upper tract urothelial carcinoma at time of radical nephroureterectomy: results from a multicenter Norwegian external validation study. World J Urol. 2020 Mar;38(3):717-723.
• Elin Ersvær, Tarjei S. Hveem, Ljiljana Vlatkovic, Bjørn Brennhovd, Andreas Kleppe, Kari Anne Tobin, Manohar Pradhan, Karolina Cyll, Håkon Wæhre, David J. Kerr, Håvard E. Danielsen. Prognostic value of DNA ploidy and automated assessment of stroma fraction in prostate cancer. Int J Cancer. 2020, 147(4), 1228-1234
• Elin Ersvær, Wanja Kildal, Ljiljana Vlatkovic, Karolina Cyll, Manohar Pradhan, Andreas Kleppe, Tarjei S. Hveem, Hanne A. Askautrud, Marco Novelli, Håkon Wæhre, Knut Liestøl, Håvard E. Danielsen. Prognostic value of mitotic checkpoint protein BUB3, cyclin B1, and pituitary tumor-transforming 1 expression in prostate cancer. Mod Pathol. 2020, 33(5), 905-915.

201​9​

• Christiansen O, Bratt O, Haug ES, Vaktskjold A, Selnes A, Jordhøy M. TECLA -an electronic database for prostate cancer patients and its use in clinical practice. Scan J Urol. 2019 Jul 2:1-6.
• Haug ES. Delay in haematuria – how can we improve? Scand J Urol 2018; 52: 459-60.
• Malmström PU, Haug ES, Boström PJ, Gudjonson S, Jensen JB. Progress towards a Nordic standard for the investigation of hematuria. Scand J Urol 2019; 53(1): 1-6
• Oedorf K, Haug ES, Liedberg F, Järvinen R, Jensen JB, Arum CJ, Lam CW. Perioperative management of radical cystectomy in the Nordic countries. Scand J Urol 2018; 53(1): 51-55.
• Nilssen Y, Brustugun OT, Eriksen MT, Gulbrandsen J, Haug ES, Naume B, Møller B. Decreasing waiting time for treatment before and during implementation of cancer patient pathways in Norway. Cancer Epidemiology 2019 May 27; 61: 59-69.

201​​8​​

• Grönberg H, Eklund M, Picker W, Aly M, Jäderling F, Adolfsson J, Landquist M, Haug ES, Ström P, Carlsson S, Nordström T. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. Eur Urol. 2018; 74:  722-728
• Andreassen B, Grimsrud T, Haug ES. Bladder Cancer Survival: Women better off in the long run. Eur J Cancer. 2018 Apr 7; 95: 52-58
• Villmones HC, Haug ES, Ulvestad E, Grude N, Stenstad T, Halland A, Kommedal Ø. Species level description of the human ileal bacterial microbiota Sci Rep. 2018 Mar 16;8(1):4736
• Löffeler S, Halland A, Nikitenko A, Weedon-Fekjær H, Ellingsen CL, Haug ES. High Norwegian Prostate Cancer Mortality: Evidence of over-registration. Scand J Urol. 2018 Jan 11:1-7

2017​​

• Nordström T, Picker W, Aly M, Jäderling F, Adolfsson J, Ström P, Haug ES, Eklund M, Carlsson S, Grönberg H. Detection of prostate cancer using a multistep approach with PSA, the Stockholm3 test and targeted biopsies - the STHLM3 MRI project. Eur Urol Focus 2017 Dec; 3: 526-528
• Cyll K, Ersvær E, Vlatkovic L, Pradhan M, Kildal W, Kjær MA, Hveem TS, Carlsen B, Gil S, Löffler S, Haug ES, Sooriakumaran P, Wæhre H and  Danielsen HE. Tumour heterogeneity poses a significant challenge to cancer biomarker research. Br J Cancer 2017; 117(3): 367-75
• Haug ES. Hva er mange og når er det nok? Tidsskr Nor Laegeforen. 2017 Apr 4;137(7):505
• Andreassen B, Myklebust TÅ, Haug ES. Crude mortality and loss of life expectancy of patients diagnosed with urothelial carcinoma of the urinary bladder in Norway. Scand J Urol 2017; 13:6-11
• Sebakk KS, Haug ES, Gullan D, Grov EK. Health related Quality of Life in Prostate cancer patients' – treatment comparisons.  International Journal of Urological Nursing  Int J Urol Nurs 2017; 11(2):98-105
• Wanja Kildal, Manohar Pradhan, Karolina Cyll, Jørn E. Jacobsen, Gunnar B. Kristensen, Håvard E. Danielsen. Properties of cancer cell DNA affects the prognosis. Tidsskr Nor Laegeforen. 2017, 137(19) 

 

• ​Institutt for kreftgenetikk og informatikk, Oslo Universitetssykehus
• Scandinavian Prostate Cancer Group (SPCG)
• Institutt for kreftforskning, Oslo Universitetssykehus
• Sykehuset Telemark HF
• Drammen sykehus- Vestre Viken
• Patologiavdeling, Sykehuset i Vestfold HF
• Mikrobiologisk avdeling, Sykehuset i Vestfold HF

• ​Scandinavian Prostate Cancer Group
• Sykehuset i Vestfold HF
• Institutt for kreftgenetikk og informatikk, Oslo Universitetssykehus
• Sykehuset Telemark HF
• Institutt for kreftforskning, Oslo Universitetssykehus
• Felles prostatasenter for Telemark, Vestfold og Vestre Viken ​